| answer text |
<p>In the vast majority of instances, payments required under the 2024 Voluntary Scheme
for Branded Medicines Pricing, Access and Growth will be affordable for companies,
or can be mitigated by standard price increase processes. In exceptional circumstances
only, the scheme allows companies to apply to increase their National Health Service
list price, and for older medicines to reduce their top-up payment percentage, even
when their wider portfolio is otherwise profitable. To qualify, a product must be
demonstrably uneconomic to supply, there must be clear evidence that supply disruption
would otherwise occur, and this disruption must have a negative impact on patients
or the NHS. The Department already has processes and committees to consider applications
for exceptional circumstances, established under previous pricing schemes.</p>
|
 |
